新药或可逆转糖尿病

2017-04-06 晋楠 中国科学报

无须注射胰岛素,不需要避开甜食—— 一种日常药物可逆转小鼠糖尿病症状,为糖尿病人将血糖水平保持在安全限度以内提供了一种更加容易的方法。

无须注射胰岛素,不需要避开甜食—— 一种日常药物可逆转小鼠糖尿病症状,为糖尿病人将血糖水平保持在安全限度以内提供了一种更加容易的方法。

2016年,英国糖尿病患者人数超过400万,10年来增加了65%。其中有350万人已经确诊,但仍有55万人据认为存在Ⅱ型糖尿病,这种疾病与超重有关,可能随着年龄增长而发生。

很多人在衰老时会产生Ⅱ型糖尿病,因为他们的身体对胰岛素的反应变弱,胰岛素是控制人体血液中有多少糖循环的荷尔蒙。一些人可以通过坚持严格限制的饮食或利用药物去除血液系统中的糖从而控制这一症状,但很多情况下这些方法具有副作用,如体重增加或腹泻。这些药物仅可以控制疾病,而不能逆转它。

现在,一种可恢复身体对胰岛素敏感性的药物可以使其更容易控制发达国家的糖尿病高潮,因为这些国家的肥胖率正在上升。美国加州大学圣迭戈分校的Stephanie Stanford和团队发现,给小鼠服用该药物可影响胰岛素信号,恢复其控制血糖水平的能力。

这种药物可每天口服,在小鼠体内并未见到任何负效应。“这可以形成治疗Ⅱ型糖尿病的新策略。”Stanford说,该团队认为药物会减少依赖胰岛素注射的患者人数。“如果这种新药可以像描述的那样起作用,它可以用于逆转胰岛素耐受性,但我们首先要知道它是否安全。”英国糖尿病协会的Emily Burns说。

据悉,该药物可通过限制一种叫作酪氨酸磷酸酶(LMPTP)的低分子质量蛋白而起作用,它似乎有助于细胞失去对胰岛素的敏感性。通过限制LMPTP,该药物可重新唤醒细胞表面的胰岛素受体,特别是肝脏的胰岛素受体,它通常在发现胰岛素后吸收血液中过多的糖。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=186001, encodeId=9ac4186001a6, content=新药新突破,值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Apr 08 15:12:38 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185782, encodeId=7aec185e820c, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Apr 07 13:27:39 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185566, encodeId=e39a18556630, content=很好!突破性的发现,值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Apr 06 15:19:18 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185564, encodeId=35fa1855647f, content=新突破,很棒的!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Apr 06 14:29:22 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185551, encodeId=cfa218555148, content=长知识了,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Thu Apr 06 13:09:18 CST 2017, time=2017-04-06, status=1, ipAttribution=)]
    2017-04-08 明天会更好!

    新药新突破,值得分享!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=186001, encodeId=9ac4186001a6, content=新药新突破,值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Apr 08 15:12:38 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185782, encodeId=7aec185e820c, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Apr 07 13:27:39 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185566, encodeId=e39a18556630, content=很好!突破性的发现,值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Apr 06 15:19:18 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185564, encodeId=35fa1855647f, content=新突破,很棒的!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Apr 06 14:29:22 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185551, encodeId=cfa218555148, content=长知识了,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Thu Apr 06 13:09:18 CST 2017, time=2017-04-06, status=1, ipAttribution=)]
    2017-04-07 明天会更好!

    学习过了,很好值得分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=186001, encodeId=9ac4186001a6, content=新药新突破,值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Apr 08 15:12:38 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185782, encodeId=7aec185e820c, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Apr 07 13:27:39 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185566, encodeId=e39a18556630, content=很好!突破性的发现,值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Apr 06 15:19:18 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185564, encodeId=35fa1855647f, content=新突破,很棒的!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Apr 06 14:29:22 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185551, encodeId=cfa218555148, content=长知识了,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Thu Apr 06 13:09:18 CST 2017, time=2017-04-06, status=1, ipAttribution=)]
    2017-04-06 明天会更好!

    很好!突破性的发现,值得分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=186001, encodeId=9ac4186001a6, content=新药新突破,值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Apr 08 15:12:38 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185782, encodeId=7aec185e820c, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Apr 07 13:27:39 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185566, encodeId=e39a18556630, content=很好!突破性的发现,值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Apr 06 15:19:18 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185564, encodeId=35fa1855647f, content=新突破,很棒的!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Apr 06 14:29:22 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185551, encodeId=cfa218555148, content=长知识了,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Thu Apr 06 13:09:18 CST 2017, time=2017-04-06, status=1, ipAttribution=)]
    2017-04-06 明天会更好!

    新突破,很棒的!!!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=186001, encodeId=9ac4186001a6, content=新药新突破,值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Apr 08 15:12:38 CST 2017, time=2017-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185782, encodeId=7aec185e820c, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Fri Apr 07 13:27:39 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185566, encodeId=e39a18556630, content=很好!突破性的发现,值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Apr 06 15:19:18 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185564, encodeId=35fa1855647f, content=新突破,很棒的!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Apr 06 14:29:22 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185551, encodeId=cfa218555148, content=长知识了,不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=101c2041447, createdName=1881e9c2b1m, createdTime=Thu Apr 06 13:09:18 CST 2017, time=2017-04-06, status=1, ipAttribution=)]
    2017-04-06 1881e9c2b1m

    长知识了,不错

    0

相关资讯

重磅!阿斯利康药物奥拉帕尼在卵巢癌3期临床试验中显著延长生存期

2017年3月21日讯 /生物谷BIOON /——一项评估阿斯利康PARP抑制剂奥拉帕尼(Lynparza)作为卵巢癌维持疗法的3期临床试验表明与安慰剂相比,该药物可以显著延长病人生存期。这项试验表明该药物可以显著延长携带生殖系BRCA突变(gBRCA)、复发且对铂类药物的化疗无反应的卵巢癌病人的无进展生存期(PFS)。试验期间采用300 mg的奥拉帕尼药片进行治疗,一日服用两次。这项随机

你知道新药的名字是怎么起的吗?

在美国一个国家中就有超过3万种独创药物的情况下,想出一个独特的药物名称并不容易。虽然这些药名看起来像是喝醉了酒的拼字游戏玩家脑洞大开的产物,它们通常是创意名称专业人事绞尽脑汁的努力和为增加FDA批准机率的明确策略相结合的结果。

Development:体外“迷你器官”将如何助力新药研发?

过去10年来体外细胞培养技术取得了快速的发展,现在,细胞培养已经不只是传统的平面培养模式,通过各种方式可以使细胞在体外也能形成三维结构。通过3D细胞培养技术,科学家们现在已经能够在实验室里制造出多种微缩版的人体器官,这包括肝、胰、胃、心、肾等等,这些“迷你”器官在体外模拟疾病过程以及测试药物方面有着广泛的用途。近日,《Development》杂志以专刊的形式回顾了这一领域的最新发展。

俄罗斯研究人员尝试利用神经网络研发新药

来自俄罗斯 Mail.ru 集团、Insilico Medicine 医药公司、莫斯科物理技术学院的研究人员首次尝试利用神经网络研制新的药物。他们试图教会神经网络“思考”并创造出新的分子结构,进而生成一些新的有前景的药物成分。该研究结果发表在《Оncotarget》杂志上。

Cell:科学家发现治疗2型糖尿病的新药

3月23日Cell上刊登的一篇文章报道了科学家发现了一系列化合物可以治疗2型糖尿病。新化合物通过乙酰化PGC-1α起作用,降低糖尿病模型动物血液中的血糖水平显著改善它们的健康。

美国 FDA 今日批准十年来帕金森病新药

今日(3 月 22 日),由意大利赞邦集团(Zambon)及 Newron 制药公司合作研发的帕金森药物 Xadago(safinamide)获美国 FDA 批准上市,这也是美国在十多年来首个获批用于治疗帕金森病的新化学实体(New Chemical Entity)。